Group Therapy Compared With Educational Materials in Patients With Prostate Cancer

NCT00002848 | Completed

• 5 other identifiers: CDR0000065087URCC-U9994NCI-CCC-94-32URCC-9994P(A)NCI-P96-0072
• Study Type: interventional
• Target: 480
• Locations: 1 country
• Sites: 7

Brief Summary

RATIONALE: Developing coping strategies may help improve the quality of life of patients with prostate cancer. PURPOSE: This randomized clinical trial is comparing the effect of group therapy with written educational materials on the quality of life of men with stage I or stage II prostate cancer.

Conditions

Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment

Keywords

stage I prostate cancer; stage IIB prostate cancer; stage IIA prostate cancer; psychosocial effects of cancer and its treatment

Interventions

psychosocial assessment and care PROCEDURE

quality-of-life assessment PROCEDURE

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Biopsy-proven prostate cancer diagnosed within 1 year prior to entry * Clinical stage I/II (T1b-c or T2, N0 or Nx, M0) disease * Pathologic local upstaging (e.g., to T3) allowed * No Nx disease if pathologic or partial pathologic (e.g., lymph node biopsy or dissection) staging performed * No major psychiatric illness requiring hospitalization or medication other than depression or anxiety for less than 1 year * No second malignancy within 10 years except nonmelanomatous skin cancer * Clinical follow-up by a urologist, medical oncologist, or radiation therapist required at least semi-annually PATIENT CHARACTERISTICS: Age * Not specified Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * See Disease Characteristics PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Gary Morrow: lead
• National Cancer Institute (NCI): collaborator

Study Sites (7)

CCOP - Western Regional, Arizona

Phoenix, Arizona, 85006-2726, United States

Location

Stanford Cancer Center at Stanford University Medical Center

Stanford, California, 94305-5718, United States

Location

CCOP - Wichita

Wichita, Kansas, 67214-3882, United States

Location

CCOP - Kalamazoo

Kalamazoo, Michigan, 49007-3731, United States

Location

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, 14642, United States

Location

CCOP - Columbus

Columbus, Ohio, 43206, United States

Location

CCOP - Northwest

Tacoma, Washington, 98405-0986, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Psychiatric Rehabilitation

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Rehabilitation; Therapeutics; Health Services; Health Care Facilities Workforce and Services

Study Officials

• Gary R. Morrow, PhD, MS

  James P. Wilmot Cancer Center

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director, URCC CCOP Research Base

Study Record Dates

• First Submitted: November 1, 1999
• First Posted: January 27, 2003
• Study Start: April 1, 1997
• Primary Completion: September 1, 2004
• Study Completion: September 1, 2004
• Last Updated: March 5, 2013

Record last verified: 2013-03

Locations

US (7)